VP 002 - Varsity Pharmaceuticals
Alternative Names: VP-002 - Varsity PharmaceuticalsLatest Information Update: 28 Feb 2022
At a glance
- Originator Varsity Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 11 Feb 2022 Preclinical trials in Pancreatic cancer in United Kingdom (unspecified route), prior to February 2022 (Varsity Pharmaceuticals pipeline, February 2022)
- 11 Feb 2022 Varsity Pharmaceuticals plans a clinical trial for Pancreatic cancer (Combination therapy), in 2023 (Varsity Pharmaceuticals pipeline, February 2022)